Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 13/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KLK1 | P06870 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31591074 | 0.88 | KLKB1 (0.61) | KLKB1KDM4EKLK1L3MBTL1GRM2 | |
| SCHEMBL31591087 | 0.86 | KLKB1 (0.46) | KLKB1KDM4EALDH1A1KLK1LMNA | |
| SCHEMBL2272882 | 0.84 | L3MBTL1 (0.57) | KLKB1KDM4EALDH1A1L3MBTL1HSD17B10 | |
| SCHEMBL30739075 | 0.84 | GRM2 (0.48) | KLKB1KDM4EALDH1A1KLK1LMNA | |
| SCHEMBL17696410 | 0.82 | KLKB1 (0.55) | KLKB1KDM4EALDH1A1KLK1LMNA | |
| SCHEMBL30739119 | 0.81 | KLKB1 (0.76) | KLKB1KLK1 | |
| SCHEMBL31591076 | 0.80 | KLKB1 (0.51) | KLKB1KDM4EALDH1A1KLK1LMNA | |
| SCHEMBL31591066 | 0.79 | KDM4E (0.44) | KLKB1KDM4EALDH1A1KLK1LMNA | |
| SCHEMBL22183009 | 0.79 | L3MBTL1 (0.49) | L3MBTL1 | |
| SCHEMBL15964732 | 0.79 | KLKB1 (0.60) | KLKB1KDM4EALDH1A1LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120051460-A | Plasma kallikrein inhibitors | 瑞泽路特有限公司 | 2025-05-27 | — | — | CN | disclosed |